ArticleJournal of clinical hypertension (Greenwich, Conn.)2021
Accuracy of the novel Peguero Lo-Presti criterion for electrocardiographic detection of left ventricular hypertrophy in a black African population.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- PERFORMANCE OF THE PEGUERO-LO PRESTI CRITERIA FOR THE DIAGNOSIS OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH CARDIAC DISEASE IN IBADAN, NIGERIA.Annals of Ibadan postgraduate medicine · 2024Article
- Do We Need New Electrocardiographic Criteria for Left Ventricular Hypertrophy? The Case of the Peguero-Lo Presti Criterion. A Narrative Review.American journal of hypertension · 2024Review
- Diagnostic Ability of Peguero-Lo Presti Electrocardiographic Left Ventricular Hypertrophy Criterion in Severe Aortic Stenosis.Journal of clinical medicine · 2021Article
- Accuracy of the novel Peguero Lo-Presti criterion for electrocardiographic detection of left ventricular hypertrophy in a black African population.Journal of clinical hypertension (Greenwich, Conn.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnostic accuracy of the electrocardiogram for left ventricular hypertrophy (LVH) is limited. Recently, Peguero and collaborators proposed a novel voltage criterion for its detection with reportedly higher accuracy than the commonly used Cornell and Sokolow-Lyon criteria. While studies done in various populations have confirmed it, there are no available data from black African populations. We conducted a cross-sectional study in a population from Cameroon to compare the Peguero-Lo Presti criterion to the older Cornell, Sokolow-Lyon, and Cornell product criteria, pertaining to their sensitivity, specificity, and area under the receiver operating characteristic curve (AUC), with echocardiography as the reference standard. The study population consisted of 238 participants (54.2% female) with a mean age of 58 (SD 13) years. On echocardiography, the prevalence of LVH was 45.3% (n = 108). The sensitivity was 48.14%, 63.89%, 63.89%, and 67.29% for the Sokolow-Lyon, Peguero-Lo Presti, Cornell, and Cornell product criteria, respectively. The specificity was 73.84%, 75.97%, 79.23%, and 82.31% for the Peguero-Lo Presti, Cornell product, Cornell, and Sokolow-Lyon criteria, respectively. The overall accuracy of the Peguero-Lo Presti (AUC = 0.689) was not significantly different from that of the Cornell (AUC = 0.714), the Cornell product (AUC = 0.717), and the Sokolow-Lyon (AUC = 0.652) (all p ˃ .05). Hypertension and gender influenced the agreement between ECG criteria and echocardiography in the detection of LVH. In conclusion, in this black African population, Peguero-Lo Presti was not significantly more or less accurate than Cornell or Sokolow-Lyon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.